Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
Serb SA's Amifampridine Serb (amifampridine) Receives Approval in Europe
Jacobus Pharm's New Drug, Ruzurgi (Amifampridine) Receives approval in the U.S.
CORAL GABLES, Fla., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported that the U.S. Court of Appeals for the 11th Circuit has issued a mandate directing the District Court that heard Catalyst's claim against the FDA to enter summary judgment in favor of Catalyst in its lawsuit against the FDA, thereby vacating the FDA's approval of Ruzurgi® (Jacobus Pharmaceutical Company's amifampridine product).
Enforcement Report - Week of October 6, 2021
Coral Gables, Fla.-based Catalyst Pharmaceuticals received a positive decision from the 11th Circuit Court of Appeals over a suit against the U.S. Food and Drug Administration’s (FDA) approval of a competitor’s amifampridine product.